# Core C:  Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core

> **NIH NIH P01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $380,670

## Abstract

CORE C ABSTRACT
Patient-derived Xenograft (PDX) and Syngeneic Mouse Melanoma Core services.
Despite recent development of targeted therapies and immunotherapies for metastatic human melanoma,
innate, adaptive and acquired resistance arise and limit clinical survival benefits. This core will subserve the
overarching goals and specific aims of each of the three Projects in this PPG. Defining resistance mechanisms
in an in vitro system is an important first step but is limited in its capacity to recapitulate inter- and intra-tumor
heterogeneity and incapable of reproducing immune and stromal environmental impacts. The development of
Patient-derived Xenograft (PDX) models that maintain the characteristics of the patient's tumor will ensure
clinical and in vivo relevance of proposed studies in each Project in this PPG. The PDX and murine melanoma
core aims to perform a prospective collection of tumor biopsies in order to create an extensive library of fully
characterized PDX models. The core will provide access to a biobank of PDX models that have been developed
from biopsy samples provided by the Core B and from outside collaborators as well as murine melanoma
models representing the genomic diversity of metastatic human melanoma. It will also generate models of
acquired resistance to currently FDA-approved or clinically-tested targeted therapies and key combinations proposed in
this PPG. We will also generate cell lines from PDX models to enable investigators of the Projects to perform
first-level mechanistic analyses. Finally, the core will generate a suite of temporal/spatial multi-omic data that
can be mined by each of the Projects to identifiy specific models that would be initially used as proof-of-
concepts and later to assemble panels with sufficient diversity to evaluate reproducibility or biologic effects
restricted to certain genomic, epigenomic or immunologic contexts.

## Key facts

- **NIH application ID:** 10693154
- **Project number:** 5P01CA244118-04
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Gatien P Moriceau
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $380,670
- **Award type:** 5
- **Project period:** 2020-09-11 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10693154

## Citation

> US National Institutes of Health, RePORTER application 10693154, Core C:  Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core (5P01CA244118-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10693154. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*